Harmony Biosciences Reports Strong 2025 Financial Results and Reiterates 2026 Net Revenue Guidance of Over $1 Billion Feb 24, 2026 07:30AM
Harmony Biosciences Holdings Inc. (HRMY) PT Raised to $37 at Goldman Sachs Jan 12, 2026 10:10AM
Harmony Biosciences forecasts WAKIX revenue to exceed $1 billion in 2026 Jan 12, 2026 08:07AM
Harmony Biosciences Guides to Over $1 Billion in WAKIX® Revenue in 2026; Advancing Robust Late-Stage Pipeline With Potential for Long-term Value Creation Jan 12, 2026 08:05AM
Harmony Biosciences shows seizure reduction in dravet syndrome trial Dec 8, 2025 08:05AM


Dec 8, 2025 08:05AM Harmony Biosciences Presents Clinically Meaningful Open-Label Extension Study Effectiveness Data for EPX-100 in Dravet Syndrome
Dec 3, 2025 06:43AM H.C. Wainwright Reiterates Buy Rating on Harmony Biosciences Holdings Inc. (HRMY)
Dec 2, 2025 08:05AM Harmony Biosciences to present EPX-100 data at epilepsy meeting
Dec 2, 2025 08:05AM Harmony Biosciences to Present New Open-Label Extension Data from Phase 3 ARGUS Trial at the 2025 American Epilepsy Society Annual Meeting
Nov 4, 2025 07:30AM Harmony Biosciences Reports Strong Q3 2025 Financial Results; Recently Raised 2025 Revenue Guidance to $845-$865M
Aug 26, 2025 08:05AM Harmony Biosciences to Present Rare Epilepsy Data at the 36th International Epilepsy Congress
Aug 5, 2025 07:30AM Harmony reports Q2 revenue growth, reaffirms 2025 guidance
Aug 5, 2025 07:30AM Harmony Biosciences Reports Strong Q2 2025 Financial Results and Reaffirms 2025 Revenue Guidance; On Track to Announce Fragile X Topline Data From Phase 3 Registrational Trial in Q3 2025
May 6, 2025 07:30AM Harmony Biosciences Reports Strong Q1 2025 Financial Results, Highlights Advancement of Its Pipeline and Upcoming Catalysts, and Reaffirms 2025 Revenue Guidance ​
Feb 25, 2025 07:30AM Harmony Biosciences Reports Strong 2024 Financial Results and Reiterates 2025 Net Revenue Guidance; Highlights 2025 Catalysts in Sleep/Wake and Fragile X Syndrome Development Programs
Oct 29, 2024 07:30AM HARMONY BIOSCIENCES REPORTS STRONG THIRD QUARTER 2024 FINANCIAL RESULTS AND HIGHLIGHTS CATALYST-RICH, LATE-STAGE PIPELINE POISED TO DELIVER ONE OR MORE NEW LAUNCHES EVERY YEAR OVER NEXT FIVE YEARS
Oct 1, 2024 08:47AM Harmony Biosciences (HRMY) Highlights New Data, Robust Late-stage Pipeline With Near-term Value Creation Opportunities And Its Bold New Vision At Investor Day
Oct 1, 2024 08:45AM HARMONY BIOSCIENCES HIGHLIGHTS NEW DATA, ROBUST LATE-STAGE PIPELINE WITH NEAR-TERM VALUE CREATION OPPORTUNITIES AND ITS BOLD NEW VISION AT INVESTOR DAY
Aug 6, 2024 07:30AM Harmony Biosciences Reports Strong Second Quarter 2024 Financial Results and Advances Pitolisant High-Dose Program Toward Expected PDUFA Date in 2028
Aug 6, 2024 07:30AM Harmony Biosciences Reports Strong Second Quarter 2024 Financial Results and Advances Pitolisant High-Dose Program Toward Expected PDUFA Date in 2028